Life expectancy estimates as a key factor in over-treatment: the case of prostate cancer.
暂无分享,去创建一个
Marc Colonna | Michelle Kelly-Irving | Cyrille Delpierre | Antoine Buemi | Simona Bara | Sébastien Lamy | C. Delpierre | A. Guizard | B. Trétarre | S. Lamy | P. Grosclaude | M. Kelly-Irving | M. Colonna | A. Buemi | M. Velten | F. Molinié | S. Bara | Michel Velten | A. Woronoff | Pascale Grosclaude | Anne-Valérie Guizard | Florence Molinié | Brigitte Tretarre | Anne-Sophie Woronoff | Bénédicte Lapôtre-Ledoux | B. Lapôtre-Ledoux | B. Lapôtre‐Ledoux
[1] S. Duffy,et al. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening , 2009, British Journal of Cancer.
[2] L. Bouter,et al. How to measure comorbidity. a critical review of available methods. , 2003, Journal of clinical epidemiology.
[3] E W Steyerberg,et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. , 2006, The Journal of urology.
[4] P. Walsh,et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.
[5] M. Zelen,et al. Overdiagnosis in early detection programs. , 2004, Biostatistics.
[6] L. Holmberg,et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.
[7] Ruth Etzioni,et al. Estimating Lead Time and Overdiagnosis Associated with PSA Screening from Prostate Cancer Incidence Trends , 2008, Biometrics.
[8] Peter H Gann,et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.
[9] J. Hugosson,et al. Lead time associated with screening for prostate cancer , 2004, International journal of cancer.
[10] A. Vickers,et al. Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[11] Josephine Hegarty,et al. Radical prostatectomy versus watchful waiting for prostate cancer. , 2010, The Cochrane database of systematic reviews.
[12] A. Méjean,et al. Dépistage du cancer de la prostate , 2003 .
[13] R A Stephenson,et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. , 2000, JAMA.
[14] Dirk F Moore,et al. Impact of comorbidity on survival among men with localized prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Fryback,et al. The impact of co-morbidity on life expectancy among men with localized prostate cancer. , 1996, The Journal of urology.
[16] Angela Mariotto,et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.
[17] S. Duffy,et al. Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia , 2006, British Journal of Cancer.
[18] Harry J de Koning,et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. , 2003, Journal of the National Cancer Institute.
[19] P. Walsh,et al. Radical prostatectomy versus watchful waiting in early prostate cancer. , 2005, The Journal of urology.
[20] A. Villers,et al. [Competitive morbidity ant its impact on life expectancy: evaluation and inclusion in the therapeutic decision regarding localized prostatic cancer]. , 2001, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[21] A. D'Amico,et al. NCCN clinical practice guidelines in oncology: prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.
[23] J. Hugosson,et al. Would prostate cancer detected by screening withprostate‐specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population‐based studies in Sweden , 2000, BJU international.
[24] P. Carroll,et al. 20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .
[25] K. Armstrong,et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. , 2006, JAMA.
[26] S. Greenfield,et al. Overtreatment of men with low‐risk prostate cancer and significant comorbidity , 2011, Cancer.
[27] T. Tammela,et al. Lead-time in prostate cancer screening (Finland) , 2002, Cancer Causes & Control.
[28] P. Schellhammer,et al. Patients’ Survival Expectations before Localized Prostate Cancer Treatment by Treatment Status , 2009, The Journal of the American Board of Family Medicine.